Updated Results From Phase I Trial of AMG 420, an Anti-BCMA Bispecific T-Cell Engager, in Patients With Relapsed/Refractory Multiple Myeloma

May 31 - June 4, 2019; Chicago, Illinois
The BiTE construct AMG 420 induces rapid clinical responses, including MRD negativity, in patients with relapsed/refractory multiple myeloma.
Format: Microsoft PowerPoint (.ppt)
File Size: 212 KB
Released: June 4, 2019

Acknowledgements

Provided by the USF Health

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

This activity is supported by educational grants from
Amgen
Celgene Corporation

Related Content

Key clinical insights from Drs Suzanne Lentzsch and Saad Usmani on individualizing care for patients with MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP Released: June 17, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

From Clinical Care Options (CCO), video featuring expert insights on the integration of CAR T-cell therapy into community care

person default Caron A. Jacobson, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2021 Expired: June 13, 2022

Results of the MagnetisMM-1 phase I trial of subcutaneous elranatamab in patients with relapsed/refractory multiple myeloma from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 14, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue